Status:
COMPLETED
The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression
Lead Sponsor:
The Taub Group
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this clinical trial is to determine the safety and efficacy of scopolamine utilized in conjunction with naltrexone for the treatment of major depression.
Detailed Description
The study will be a double blinded, randomized controlled trial. The medications will be administered orally. The sample size will be 40 participants, 20 in the treatment group and 20 in the control g...
Eligibility Criteria
Inclusion
- male or female, aged 18-65
- in good health other than major depression for 8 weeks or more
- negative pregnancy test
- able to comply with instructions
- able to provide informed consent
Exclusion
- pregnant or lactating
- danger to self or others
- severe kidney or liver disease
- schizophrenia
- allergy to scopolamine or naltrexone
- glaucoma
- Monoamine oxidase (MAO) inhibitor use
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2018
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03386448
Start Date
January 1 2018
End Date
November 20 2018
Last Update
May 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Taub Group
Charlotte, North Carolina, United States, 28211